Can treatment to get cheaper in India (Credits: AI)
\n\nCancer treatment in India is set to become more affordable, with the government capping trade margins at 30% for 137 anti-cancer medicines, including several patented drugs used in targeted therapies and immunotherapy. The revised maximum retail prices (MRPs) will come into effect from November 9, 2026, following a decision by the National Pharmaceutical Pricing Authority (NPPA). The move is aimed at curbing excessive mark-ups and reducing the financial burden on cancer patients and their families.
\n\nThe list of 137 medicines includes pembrolizumab, nivolumab, osimertinib, palbociclib, olaparib, bevacizumab and daratumumab, among others. These medicines are used in the treatment of different cancers, including certain types of lung, breast, ovarian and blood cancers.
\n\nThe list also covers drugs such as abemaciclib, ribociclib and venetoclax. The pricing intervention applies to specified non-scheduled formulations containing the listed drugs, whether sold individually or in combination, and across different strengths and dosage forms. Patented medicines are also covered, unless an applicable exemption has been granted under the Drugs (Prices Control) Order, 2013.
\n\nThe NPPA has capped trade margins at 30% of the MRP, excluding Goods and Services Tax (GST). This corresponds to a mark-up of 42.86% on…
Original source: https://www.timesnownews.com/lifestyle
